» Articles » PMID: 35152853

MiR-148b-3p, As a Tumor Suppressor, Targets Son of Sevenless Homolog 1 to Regulate the Malignant Progression in Human Osteosarcoma

Overview
Journal Bioengineered
Date 2022 Feb 14
PMID 35152853
Authors
Affiliations
Soon will be listed here.
Abstract

Osteosarcoma (OS) is a malignant tumor that occurs in children and adolescents. Previous studies reported a low expression of miR-148b-3p in OS, but its biological function in OS remains obscure. This study aimed to explore the role of miR-148b-3p in OS progression. Herein, the expression of miR-148b-3p and son of sevenless homolog 1 (SOS1) both in OS tissues and cells were examined using quantitative real-time polymerase chain reaction and Western blotting assay. miR-148b-3p mimic or inhibitor, pcDH-SOS1 plasmid or si-SOS1 and agomir-miR-148b-3p were constructed for cell transfection. , the biological effect of miR-148b-3p was determined employing MTT, EdU, colony formation, flow cytometry, transwell and wound healing assay, separately. The target relationship between SOS1 3'-untranslated region (3'-UTR) and miR-148b-3p was analyzed using dual-luciferase reporter gene. , the inhibition of agomir-miR-148b-3p in mice was evaluated via a xenograft mouse model. miR-148b-3p was noticeably low-expressed in OS tissues and cells, and miR-148b-3p over-expression in OS cells suppressed the growth, migration and invasion, induced apoptosis. The effect of miR-148b-3p-inhibitor on cell biological behavior is opposite to that of miR-148b-3p over-expression. Conversely, The expression of SOS1 was significant higher in OS tissues and cells, miR-148b-3p targeted and was negatively associated with the expression level of SOS1. In addition, the anti-tumor effect of miR-148b-3p was reversed by SOS1. Importantly, we demonstrated that the tumor growth of stably over-expressed miR-148b-3p human MG-63 cells was obviously reduced in tumor-bearing mice. These data highlighted that miR-148b-3p might be as a promising therapeutic target for OS.

Citing Articles

MicroRNA miR-331-3p suppresses osteosarcoma progression via the Bcl-2/Bax and Wnt/β-Catenin signaling pathways and the epithelial-mesenchymal transition by targeting N-acetylglucosaminyltransferase I (MGAT1).

Bi W, Yang M, Xing P, Huang T Bioengineered. 2022; 13(6):14159-14174.

PMID: 35758024 PMC: 9342255. DOI: 10.1080/21655979.2022.2083855.


Integrated microRNA-mRNA Expression Profiling Identifies Novel Targets and Networks Associated with Autism.

Gill P, Dweep H, Rose S, Wickramasinghe P, Vyas K, McCullough S J Pers Med. 2022; 12(6).

PMID: 35743705 PMC: 9225282. DOI: 10.3390/jpm12060920.


MicroRNA-3200-3p targeting CAMK2A modulates the proliferation and metastasis of glioma .

Wang H, Zeng Z, Yi R, Luo J, Chen J, Lou J Bioengineered. 2022; 13(3):7785-7797.

PMID: 35287547 PMC: 9208524. DOI: 10.1080/21655979.2022.2048995.

References
1.
Morrow J, Khanna C . Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies. Crit Rev Oncog. 2015; 20(3-4):173-97. PMC: 4894524. DOI: 10.1615/critrevoncog.2015013713. View

2.
Zhao R, Song J, Jin Y, Liu Y . Long noncoding RNA HOXC-AS3 enhances the progression of cervical cancer via activating ErbB signaling pathway. J Mol Histol. 2021; 52(5):991-1006. DOI: 10.1007/s10735-021-10007-z. View

3.
Fang D, Chen H, Zhu J, Wang W, Teng Y, Ding H . Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways. Oncogene. 2016; 36(11):1546-1558. PMC: 5346482. DOI: 10.1038/onc.2016.323. View

4.
Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

5.
Harrison D, Geller D, Gill J, Lewis V, Gorlick R . Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2017; 18(1):39-50. DOI: 10.1080/14737140.2018.1413939. View